

Pacira BioSciences, Inc. (PCRX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001396814

Pacira BioSciences, Inc. PCR; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 50.3; sampling error 2.5 points; lower is stronger
Rank	187 of 371
Profitability	C percentile 46.6
Solvency	B/C percentile 41.9
Growth and financing	C percentile 56.1
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$1.3B
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	none active
Inputs computable	11 of 14
Graded from	filings received through Feb 26, 2026 225 days before the rescans; latest periodic filing 10-Q received Aug 4, 2026
Last close	\$36.41 2026-10-08; market equity \$1.5B
Price used in grade	None



C, the tortoise
middle fifth of its sector; letters are fifths of the 371 graded peers


Share price, twelve months to the rescans
split-adjusted close; the letter is fixed at the rescans that set it



Rescans on file: B/C from Aug 21, 2026, C from Sep 26, 2026, B/C from Oct 3, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Feb 26, 2026

Pacira BioSciences, Inc., a Delaware corporation, is the holding company for our California operating subsidiary named Pacira Pharmaceuticals, Inc. In March 2007, we acquired Pacira Pharmaceuticals, Inc. from SkyePharma Holdings, Inc. (now Vectura Group Limited, a subsidiary of Molex Asia Holdings, Ltd.), or Skyepharma (the "Skyepharma Acquisition").


The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 46.6						
Gross profitability		45.6%	32.2%	26.7	372	2025-12-31
Return on invested capital		0.8%	9.3%	72.6	74	2025-12-31
Accruals ratio		(10.3%)	(6.6%)	40.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five consecutive annual gross margins are required
Solvency, sleeve percentile 41.9						
Twelve-month failure probability		0.07%	0.07%	49.4	248	2026-06-30
Altman Z double-prime		3.08	(0.31)	24.8	756	2025-12-31
Net debt to EBITDA		1.94x	1.82x	52.7	75	2025-12-31
Interest coverage		not computable	(4.51x)			latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31
Current ratio		4.54x	2.96x	40.7	839	2025-12-31
Growth and financing, sleeve percentile 56.1						
Revenue growth, three-year compound		not computable	10.0%			four consecutive annual observations are required
Free cash flow growth, three-year compound		5.9%	10.9%	56.8	96	2025-12-31
Reinvestment rate		(1,044.0%)	37.1%	99.0	104	2025-12-31
Asset growth, three years		(9.0%)	2.1%	67.4	704	2025-12-31
Net share issuance, one year		(12.5%)	2.5%	0.9	634	2026-02-23

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
182	Savara Inc. (SVRA)	48.9	C	short runway, fortress balance sheet
183	Biodesix Inc. (BDSX)	49.2	C	dilution
184	Evolus, Inc. (EOLS)	49.5	C	
185	Neogen Corp. (NEOG)	49.7	C	late filer
186	Nurix Therapeutics, Inc. (NRIX)	50.0	C	dilution, short runway

187	Pacira BioSciences, Inc. (PCRX) <	50.3	C
188	Neuroone Medical Technologies Corp. (NMTC)	50.5	C short runway, fortress balance sheet
189	RadNet, Inc. (RDNT)	50.8	C
190	Schrodinger, Inc. (SDGR)	51.1	C
191	Zai Lab Ltd. (ZLAB)	51.4	C
192	Recursion Pharmaceuticals, Inc. (RXXR)	51.6	C dilution, fortress balance sheet

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	0.5%	8.0%	46
Distance from 52-week high	0.0%	(31.4%)	98
EBIT to enterprise value	1.2%	(1.5%)	59
Free cash flow yield	9.4%	(1.0%)	90
Book value to price	0.46	0.28	68
Sales to price	0.50	0.31	66
Composite equity issuance, five years	(9.6%)	20.3%	15
Relative strength against the sector, log excess return	(0.21)	(0.14)	46

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	pass
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$205.9M
Operating cash flow, four quarters	\$187.7M
Months of runway	not finite
Days since last periodic filing	66 (10-Q received Aug 4, 2026)
Median daily dollar volume, 63 sessions	\$13.6M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$726.4M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
2	cost of revenue	us-gaap:CostOfRevenue	\$149.7M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
3	assets	us-gaap:Assets	\$1.3B	2025-12-31	2026-02-26	10-K	0001628280-26-012297
4	operating income	us-gaap:OperatingIncomeLoss	\$19.2M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraord	\$16.9M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
6	income tax	us-gaap:IncomeTaxExpenseBenefit	\$9.8M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
7	total debt	us-gaap:LongTermDebt	\$372.2M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
8	book equity	us-gaap:StockholdersEquity	\$693.1M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$158.5M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
10	total debt	us-gaap:LongTermDebt	\$585.3M	2024-12-31	2026-02-26	10-K	0001628280-26-012297
11	book equity	us-gaap:StockholdersEquity	\$778.3M	2024-12-31	2026-02-26	10-K	0001628280-26-012297

12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$276.8M	2024-12-31	2026-02-26	10-K	0001628280-26-012297
13	net income	us-gaap:NetIncomeLoss	\$7.0M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$152.0M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
15	assets	us-gaap:Assets	\$1.6B	2024-12-31	2026-02-26	10-K	0001628280-26-012297
16	current assets	us-gaap:AssetsCurrent	\$548.0M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
17	current liabilities	us-gaap:LiabilitiesCurrent	\$120.6M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$199.3M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
19	liabilities	us-gaap:Liabilities	\$571.8M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
20	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$91.0M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
21	operating income	us-gaap:OperatingIncomeLoss	\$87.7M	2023-12-31	2026-02-26	10-K	0001628280-26-012297
22	interest expense	us-gaap:InterestExpense	\$20.3M	2023-12-31	2024-02-29	10-K	0001396814-24-000030
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$675.0M	2023-12-31	2026-02-26	10-K	0001628280-26-012297
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$666.8M	2022-12-31	2024-02-29	10-K	0001396814-24-000030
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$541.5M	2021-12-31	2024-02-29	10-K	0001396814-24-000030
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$15.3M	2025-12-31	2026-02-26	10-K	0001628280-26-012297
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$189.4M	2024-12-31	2026-02-26	10-K	0001628280-26-012297
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$10.6M	2024-12-31	2026-02-26	10-K	0001628280-26-012297
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$154.6M	2023-12-31	2026-02-26	10-K	0001628280-26-012297
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$15.2M	2023-12-31	2026-02-26	10-K	0001628280-26-012297
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	\$145.3M	2022-12-31	2025-02-27	10-K	0001396814-25-000041
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$30.1M	2022-12-31	2025-02-27	10-K	0001396814-25-000041
33	current assets	us-gaap:AssetsCurrent	\$745.1M	2024-12-31	2026-02-26	10-K	0001628280-26-012297
34	current liabilities	us-gaap:LiabilitiesCurrent	\$309.9M	2024-12-31	2026-02-26	10-K	0001628280-26-012297
35	assets	us-gaap:Assets	\$1.6B	2023-12-31	2025-02-27	10-K	0001396814-25-000041
36	assets	us-gaap:Assets	\$1.7B	2022-12-31	2024-02-29	10-K	0001396814-24-000030
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	40,489,894	2026-02-23	2026-02-26	10-K	0001628280-26-012297
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	46,276,241	2025-02-25	2025-02-27	10-K	0001396814-25-000041